IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS

IN8BIO, INC.

50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).
Biopsy confirmed gamma-delta T cell persistence in brain tumor microenvironment in two patients post-treatment.
Median PFS in repeat-dose patients increased 79% vs. 6.9 months for Stupp regimen.
No treatment-related serious adverse events, cytokine release syndrome, or neurotoxicity reported.
One IDH-mutant glioma patient remains alive and progression-free at 40.5 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.